AccuGenomics and 1Cell.Ai Partner to Bring Ultra-Sensitive Liquid Biopsy Testing Across Asia, with Plans for U.S. Expansion

Collaboration integrates per-sample NGS internal standards with multi-omic precision oncology platform to enhance cancer diagnostics accuracy and access

WILMINGTON, N.C. and MUMBAI, India, Oct. 13, 2025 /PRNewswire/ -- AccuGenomics, Inc., a US-based leader in next-generation sequencing (NGS) quality standards, and 1Cell.Ai, a US-based precision oncology company specializing in single-cell and liquid biopsy diagnostics, today announced a strategic collaboration to deliver ultra-sensitive, clinically actionable liquid biopsy testing through their clinical laboratory in India serving cancer patients across Asia.

Under this partnership, 1Cell.Ai will integrate AccuGenomics' Accukit™ CRC/NSCLC Internal Standards into its ultra-sensitive NGS-based OncoIndx panel to provide per-sample quality control and sensitivity verification. The company expects to process tens of thousands of patient samples in the next year, significantly increasing access to high-precision cancer testing across Asia. 1Cell.Ai also plans to introduce this assay at its Foster City, California facility to support precision multi-omic testing for the United States market soon.

The Accukit™ CRC/NSCLC Internal Standards are synthetic, gene-specific quality controls that validate assay performance and ensure sensitivity for detecting clinically relevant mutations in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). By embedding internal standards within every patient sample tested, laboratories can confirm per-sample analytical accuracy, improve reproducibility, and reduce false negatives, a critical advancement in clinical NGS testing where small-variant detection directly influences patient management and therapeutic decisions.

"We are thrilled to partner with 1Cell.Ai, a leader in multi-omic precision diagnostics," said Nick Lazaridis, President of AccuGenomics. "By integrating our Accukit™ CRC/NSCLC Internal Standards with their liquid biopsy platform, we are enabling true per-sample sensitivity and reliability, a new benchmark in cancer diagnostics. This collaboration not only strengthens cancer care in India but also lays the groundwork for their expansion into the US market."

"This collaboration represents a significant step forward in ensuring that every patient sample we analyze meets the highest standards of analytical accuracy," said Mohan Uttarwar, CEO of 1Cell.Ai. By integrating AccuGenomics' internal standards into our OncoIndx gene-panel, we can deliver ultra-sensitive, clinically actionable insights for oncologists and patients. This partnership supports our mission to make precision oncology testing both reliable and affordable, first across Asia, and soon in the United States."

About AccuGenomics

AccuGenomics, Inc. is a biotechnology tools company headquartered in Wilmington, North Carolina, specializing in the development of synthetic internal standards for next-generation sequencing (NGS). The company's Accukit™ product line provides per-sample quality control and LOD sensitivity assurance, enabling clinical laboratories and diagnostic developers to improve test diagnostic accuracy, reproducibility, and confidence in genomic data. AccuGenomics' mission is to standardize NGS testing globally, driving advancements in precision medicine.

About 1Cell.Ai

US-based 1Cell.Ai is a precision oncology company with presence in Mumbai, and Pune, India. 1Cell.Ai has a CLIA and CAP certified laboratory at Foster City, California, offering innovative Laboratory Developed tests (LDTs), first in class assays for next generation cell based liquid biopsies with true single cell multi-omic biomarker analytics to improve cancer detection, treatment monitoring, and biomarker discovery. Through innovation and accessibility, 1Cell.Ai aims to transform cancer diagnostics and advance the future of precision medicine delivering comprehensive, real-time insights that empower clinicians, researchers, and biopharma partners to make informed, personalized decisions.

Media Contact
Dan Dilks
SVP Business Development & Commercial
AccuGenomics, Inc.
402590@email4pr.com 
(609) 491-0489

Media Contact
Malini Rajagopalan, Ph.D.
VP, Marketing
1Cell.Ai
402590@email4pr.com
(858) 354-4858

Financial terms of the agreement were not disclosed.

View original content to download multimedia:https://www.prnewswire.com/news-releases/accugenomics-and-1cellai-partner-to-bring-ultra-sensitive-liquid-biopsy-testing-across-asia-with-plans-for-us-expansion-302581276.html

SOURCE AccuGenomics